

PATENT  
030639.0034.CPA2**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: John Dupre

Serial No.: 09/280,020

Filed: March 29, 1999

Title: **TREATMENT OF DIABETES**

Group Art Unit: 1644

Examiner: Nolan, P.

Box AF  
Commissioner for Patents  
Washington, D.C. 20231

23

**TERMINAL DISCLAIMER UNDER 37 C.F.R. §1.321(c)**



Dear Sir:

Amylin Pharmaceuticals, Inc., a corporation duly organized under the laws of the State of Delaware and having a principal office at 9373 Towne Centre Drive, San Diego, California 92121, being duly represented by the undersigned, is the assignee of the full title and interest in and to the above-identified Application Serial No. 09/280,020, by virtue of a deed of Assignment recorded at Reel/Frame 8440/0325, which deed of Assignment includes rights to the invention of Application Serial No. 08/737,446 and to Letters Patents granted and issued therefor, including continuations. The present application is a continuation of Application Serial No. 08/737,446.

Amylin Pharmaceuticals, Inc., hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on instant Application Serial No. 09/280,020 that would extend beyond the expiration date of the full statutory term of any patent issuing from copending Application Serial No. 08/737,446, as presently shortened by any terminal disclaimer. Amylin Pharmaceuticals, Inc. also hereby agrees that any patent granted on the instant application shall be enforceable only for and during such period that such patent and any patent issuing from copending Application Serial No. 08/737,446 are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

06/05/2002 GDUCKETT 00000001 501273 09280020  
01 FC:248 55.00 CH**CERTIFICATE OF TRANSMISSION  
(37 C.F.R. §1.8)**

I hereby certify that this paper (along with anything referred to as being attached or enclosed) is being transmitted, via facsimile, to the United States Patent and Trademark Office on the date indicated below.

  
Lisa M. McGeehan  
Date

C:\NTPort\SDILIB\NLM03\443636\_1.DOC

Received from &lt; &gt; at 5/28/02 7:16:07 PM [Eastern Daylight Time]

Terminal Disclaimer  
Serial No. 09/280,020  
Page 2 of 2

---

In making this disclaimer, Amylin Pharmaceuticals, Inc. does not disclaim the terminal part of any patent granted on the instant application that would extend beyond the expiration date of the full statutory term of any patent issuing from copending Application Serial No. 08/737,446, as presently shortened by any terminal disclaimer filed, in the event that any patent issuing from copending Application Serial No. 08/737,446: expires for failure to pay a maintenance fee, is held to be unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. §1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any other manner terminated prior to the expiration of its full statutory term, as presently shortened by any terminal disclaimer.

The undersigned, an attorney of record, is authorized to take this action on behalf of Amylin Pharmaceuticals, Inc. The Commissioner is authorized to charge the small entity fee (\$55) required under 37 C.F.R. §1.20(d) for filing this Terminal Disclaimer, as well as any additional fees that may be required during the pendency of this application, or to credit any overpayment, to Deposit Account No. 50-1273.

Respectfully Submitted,

AMYLIN PHARMACEUTICALS, INC.

By: Lisa M. McGeehan

Lisa M. McGeehan  
Reg. No. 41,185

Brobeck, Phleger & Harrison LLP  
12390 El Camino Real  
San Diego, CA 92130-2081  
Direct Dial: (858)720-2584  
Facsimile: (858)720-2555